logo-loader
viewNetscientific PLC

Netscientific expects shareholders to reject plan to delist from AIM and become private company

NetScientific has decided to postpone its general meeting.

Netscientific
Netscientific announced the proposal last month

NetScientific plc (LON:NSCI) said more than 30% of shareholders have indicated they would vote against a proposal to cancel its shares on AIM and re-register as a private company.

The shareholders sent proxy forms instructing their shares to be voted against the proposal at the general meeting, which was due to be held on March 4.

READ: NetScientific to delist from AIM and become a private company following strategic review

NetScientific said it now believes the resolution would be voted against and has decided to postpone the general meeting.

The firm, which invests in development-stage medical and healthcare businesses, announced its plan to go private last month following a strategic review of its operations.

The review concluded that the company needed a revised strategy to reduce its central functions and costs “significantly” to enable as much of its remaining cash as possible be allocated to its portfolio companies.

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read